These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Singh K; Pruski M; Bland R; Younes M; Guha S; Thosani N; Maitra A; Cash BD; McAllister F; Logsdon CD; Chang JT; Bailey-Lundberg JM Lab Invest; 2021 Feb; 101(2):177-192. PubMed ID: 33009500 [TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
9. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L Cancer Lett; 2013 Oct; 339(1):135-43. PubMed ID: 23887057 [TBL] [Abstract][Full Text] [Related]
10. Aryl Hydrocarbon Receptor Knockout Accelerates PanIN Formation and Fibro-Inflammation in a Mutant Kras -Driven Pancreatic Cancer Model. Walcheck MT; Schwartz PB; Carrillo ND; Matkowskyj KA; Nukaya M; Bradfield CA; Ronnekleiv-Kelly SM Pancreas; 2024 Sep; 53(8):e670-e680. PubMed ID: 38696422 [TBL] [Abstract][Full Text] [Related]
11. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-Catenin Gao C; Chen G; Zhang DH; Zhang J; Kuan SF; Hu W; Esni F; Gao X; Guan JL; Chu E; Hu J Cell Mol Gastroenterol Hepatol; 2019; 8(4):561-578. PubMed ID: 31330317 [TBL] [Abstract][Full Text] [Related]
13. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294 [TBL] [Abstract][Full Text] [Related]
14. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. Yu X; Liu W; Wang Z; Wang H; Liu J; Huang C; Zhao T; Wang X; Gao S; Ma Y; Wu L; Li X; Yang S; Hao J Cancer Lett; 2021 Oct; 519():289-303. PubMed ID: 34302921 [TBL] [Abstract][Full Text] [Related]
15. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Faraoni EY; Singh K; Chandra V; Le Roux O; Dai Y; Sahin I; O'Brien BJ; Strickland LN; Li L; Vucic E; Warner AN; Pruski M; Clark T; Van Buren G; Thosani NC; Bynon JS; Wray CJ; Bar-Sagi D; Poulsen KL; Vornik LA; Savage MI; Sei S; Mohammed A; Zhao Z; Brown PH; Mills T; Eltzschig HK; McAllister F; Bailey-Lundberg JM Cancer Res; 2023 Apr; 83(7):1111-1127. PubMed ID: 36720042 [TBL] [Abstract][Full Text] [Related]
16. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536 [TBL] [Abstract][Full Text] [Related]